The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy

Overview of attention for article published in BMC Cancer, January 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 4,933 followers.

RT @SEMiPYP: The MITRE trial protocol: a study to evaluate the #microbiome as a #biomarker of efficacy and toxicity in #cancer patients rec…

RT @SEMiPYP: The MITRE trial protocol: a study to evaluate the #microbiome as a #biomarker of efficacy and toxicity in #cancer patients rec…

The MITRE trial protocol: a study to evaluate the #microbiome as a #biomarker of efficacy and toxicity in #cancer patients receiving immune checkpoint inhibitor therapy by Nicola A. Thompson et al. ⤵️ https://t.co/9JESRZaLFq @BioMedCentral Cancer https://t

New article: The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy https://t.co/zbO6Voo0qr #lungcancer #oncology https://t.co/ufsBWJhqr8

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.